



# Epidemiologisches Bulletin

22. Juni 2007 / Nr. 25 – Anlage AKTUELLE DATEN UND INFORMATIONEN ZU INFEKTIONSKRANKHEITEN UND PUBLIC HEALTH

Aktualisierte Mitteilung der Ständigen Impfkommission (STIKO) am RKI:  
**Hinweise für Ärzte zum Aufklärungsbedarf über mögliche unerwünschte Wirkungen bei Schutzimpfungen/Stand: 2007**  
 – Literaturverzeichnis –

## Fachinformationen

1. FachInfo Service. In: Rote Liste® Online des Rote Liste® Service GmbH Frankfurt/Main. <http://www.rote-liste.de/Online> (Zugang 12.1.2007)

## Literatur zu speziellen Impfungen

### Cholera-Impfung

2. Cholera vaccines. WHO position paper. WER 2001; 76: 117–124

### *Diphtherie (D)-, Diphtherie-Tetanus (DT)-, Diphtherie-Tetanus-Pertussis (azellulär) (DTaP)- Impfstoff; 5- und 6-valente Impfstoffe auf DTaP-Basis (DTaP-Hib-IPV, DTaP-Hib-IPV-HB)*

3. Stratton KR, Howe CJ, Johnston RB Jr (eds.): Adverse events associated with childhood vaccines. National Academy of Sciences, Washington DC 1994, section diphtheria and tetanus toxoids, pp 67–117
4. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. MMWR 1996; 45: No RR-12, section side effects and adverse reactions following DTP vaccination, p 22
5. Schmitt HJ, Beutel K, Schwind A, et al.: Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 1997; 130: 616–623
6. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Diphtherie, S. 39–43
7. Use of DTaP vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000; 49: No. RR-13
8. Chen RT, Mootrey G, DeStefano F: Safety of routine childhood vaccinations: An epidemiological review. Pediatr Drugs 2000; 2: section DTP vaccines, pp 277–280
9. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following DTP vaccines. WHO, Geneva 2000. WHO/V&B/00.36, pp 17–25
10. Dittmann S: Combination vaccines: DTaP or DTwP vaccine combined with other antigens, such as Hib, IPV, and hepatitis B vaccine, or simultaneous administration of these vaccines. In: Side Effects of Drugs Annual 25 (ed. Aronson JK). Elsevier, Amsterdam 2002, p 382–384

## Anlage zu Ausgabe 25/2007

Mitteilung der  
 Ständigen Impfkommission  
 (STIKO) am RKI:

Hinweise für Ärzte zum  
 Aufklärungsbedarf über  
 mögliche unerwünschte  
 Wirkungen bei Schutzimpfungen  
 – Literaturverzeichnis –

Stand: Juni 2007



11. Dittmann S: Diphtheria/tetanus or diphtheria/tetanus/pertussis vaccines in combination with other vaccines. In: Side Effects of Drugs Annual 26 (ed. Aronson JK). Elsevier, Amsterdam 2003, p 356–357
12. Wharton M, Vitek C: Diphtheria toxoid. In: Plotkin SA, Orenstein WA (eds.). Vaccines. 4th ed. Saunders, Philadelphia 2004, pp 211–228
13. Edwards KM, Decker MD: Pertussis vaccine. In: Plotkin SA, Orenstein WA (eds.). Vaccines. 4th ed. Saunders, Philadelphia 2004, pp 471–528
14. Wassilak SGF, Murphy TV, Roper MH, Orenstein WA: Tetanus toxoid. In: Plotkin SA, Orenstein WA (eds.) Vaccine. 4th ed. Saunders, Philadelphia 2004, pp 745–782
15. Offit PA, Hackett CJ: Multiple vaccines and the immune system. In: Plotkin SA, Orenstein WA (eds.). Vaccines. 4th ed. Saunders, Philadelphia 2004, pp 583–1590
16. American Academy of Pediatrics: Diphtheria. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed.
17. American Academy of Pediatrics: Pertussis. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 498–520
18. American Academy of Pediatrics: Tetanus. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 648–653
19. Dittmann S: Monographs on diphtheria, tetanus toxoid, and pertussis vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 1137–1140; 2783–2790; 3325–3327
20. Diphtheria vaccines. WHO position paper. WER 2006; 81: 24–32
21. Tetanus vaccines. WHO position paper. WER 2006; 81: 198–208
22. Pertussis vaccines WHO position paper. WER 2005; 80: 31–39
23. Halsey NA: Safety of combination vaccines: perception versus reality. *Pediatr Infect Dis J* 2001; 20 (Suppl. 1): S40–S44
24. Offit PA, Quarles J, Gerber MA, Hackett ChJ, Marcuse EK, Kollman TR, Gellin BG, Landry S: Addressing parent's concerns: Do multiple vaccines overwhelm or weaken the infant's immune system? *Pediatrics* 2002; 109(1): 124–129
25. Institute of Medicine: Immunization Safety Review: Multiple immunizations and immune dysfunction. National Academy Press, Washington DC 2002. <http://www.nap.edu/catalog/10306.html> (Zugang: 26 Jan 2007)
26. Offit PA, Hackett CJ: Multiple vaccines and the immune system. In: Plotkin SA, Orenstein WA (eds.) Vaccines. 4th ed. Saunders, Philadelphia 2004, pp 1583–1590
27. Hexavalent vaccines. Global Advisory Committee on Vaccine Safety, 9–10 June 2005. WER 2005, 80: 245–246
28. American Academy of Pediatrics: Simultaneous administration of multiple vaccines. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, p 34
29. American Academy of Pediatrics: Combination vaccines. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 34–35
30. American Academy of Pediatrics: Risks and adverse events. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 39–41
31. Immunological overload. Global Advisory Committee on Vaccine Safety, 6–7 June 2006. WER 2006; 81: 273–278

#### Literatur zu Impfungen und plötzlichem Kindstod (sudden infant death syndrome – SIDS)

Ferner in Abhängigkeit von den neben DTaP im Impfstoff enthaltenen weiteren Komponenten (Haemophilus influenzae [Hib] und/oder Poliomyelitis [inaktiviert-IPV] und/oder Hepatitis B) diesbezügliche Literaturangaben.

#### Literatur zur Sicherheit und Wirksamkeit von Kombinations- und Mehrfachimpfungen

32. Fleming PJ et al.: The UK accelerated immunization programme and sudden unexpected death in infancy: case control study. *Brit Med J* 2001; 322: 822–825
33. Institute of Medicine: Immunization Safety Review: Vaccinations and sudden unexpected death in infancy. National Academy Press, Washington DC 2003. <http://www.nap.edu/catalog/10649.html> (Zugang: 26 Jan 2007)
34. Keller-Stanislawski B, Löwer J: Todesfälle im zeitlichen Zusammenhang mit Sechsfachimpfung. *Kinder- und Jugendarzt* 2003; 34: 608
35. Die Europäische Arzneimittelagentur (EMA) sieht unverändertes Nutzen/Risikoprofil für Sechsfachimpfstoffe. [http://www.pei.de/professionals/hexavalente\\_nov.pdf](http://www.pei.de/professionals/hexavalente_nov.pdf) (Zugang 2.12.03)
36. EMA: Public Statement – December 1, 2003. <http://www.emea.eu.int/pdfs/human/press/pus/588903en.pdf> (Zugang 2.12.03)
37. Scientific conclusions and grounds for amendment of the summaries of product characteristics and package leaflets presented by the EMA. <http://www.emea.europa.eu/humandocs/PDFs/EPAR/Hexavac/Hexavac-H-298-A18-655-en.pdf> (Zugang 20.12.2006)
38. American Academy of Pediatrics: Risks and adverse events. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 39–41

39. Zinka B, Rauch E, Buettner A, Rueff F, Penning R: Unexplained cases of sudden infant death shortly after hexavalent vaccination. *Vaccine* 2006; 24: 5779–5780
40. Schmitt HJ, Siegrist CA, Salmaso S, Law B, Booy R: Comment on B. Zinka et al. Unexplained cases of sudden infant death shortly after hexavalent vaccination. *Vaccine* 2006, 24: 5781–5782
41. von Kries R: Comment on B. Zinka et al. Unexplained cases of sudden infant death shortly after hexavalent vaccination. *Vaccine* 2006; 24: 5783–5784
42. Vennemann MM, Butterfass-Bahloul T, Jorch G et al.: Sudden infant death syndrome: No increased risk after immunisation. *Vaccine* 2007; 25 (2): 336–340
53. Adverse events associated with 17D-derived yellow fever vaccination – United States, 2001–2002. *MMWR* 2002; 51: 989–993
54. Yellow fever vaccine. WHO position paper. *WER* 2003; 78: 349–359
55. Monath TP: Yellow Fever vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, 1095–1176
56. Kitchener S: Viscerotropic and neurotropic diseases following vaccination with the 17D yellow fever vaccine, ARILVAX. *Vaccine* 2004; 22: 2103–2105
57. Dittmann S: Yellow fever vaccine. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 3703–3704

### FSME-Impfstoff

43. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Frühsommer-Meningoenzephalitis, S. 44–48
44. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following tick-borne encephalitis virus vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 87–88
45. Dorner F, Barret PN, Plotkin SA: Tick-Borne encephalitis virus vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 1039–1056
46. Dittmann S: Tickborne meningoencephalitis vaccine. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 3423–3424

### Gelbfieber-Impfstoff

47. Merlo C, Steffen R, Landis T, Tsai T: Possible association of encephalitis and 17D yellow fever vaccination in a 29-year-old traveller. *Vaccine* 1993; 1: 691
48. Drouet A, Chagnon A, Valance J, CarliP, Muzellec Y, Paris YF: Meningoencephalitis after immunization with 17D yellow fever virus. *Rev Med Interne* 1993; 4: 257–259
49. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Gelbfieber, S. 49–52
50. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following yellow fever vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 102–105
51. Mitteilung der Ständigen Impfkommision (STIKO) am Robert Koch-Institut: Zu Nebenwirkungen und vereinzelten Komplikationen nach Gelbfieberimpfung. *Epid Bull* 2001; 44: 336–337
52. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. *MMWR* 2002; 51: RR-17

### Haemophilus-influenzae-Impfstoff

58. Stratton KR, Howe CJ, Johnston RB Jr (eds.): Adverse events associated with childhood vaccines. National Academy of Sciences, Washington DC 1994, section *Haemophilus influenzae* Type b Vaccines, pp 236–273
59. Quast U, Thilo W, Fescharek R: Haemophilus Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Haemophilus influenzae Typ b (Hib)-Erkrankung, S. 53–56
60. Von Kries R, Schmitt HJ: Diabetes mellitus nach Hib-Impfung? *Kinderärztl Prax* 1999; 70: 589–590
61. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events associated with Haemophilus influenzae type b (Hib) vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp26–30
62. Chen RT, Mootrey G, DeStefano F: Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: section Haemophilus influenzae Type B Vaccines, pp 281–282
63. Trampisch HJ, Lange S: Diabetes mellitus nach Hib-Impfung? *Die Diskussion geht weiter. Kinderärztl Prax* 2000; 71: 6–10
64. Wenger JD, Ward J: Haemophilus influenzae vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 229–268
65. WHO Position Paper on Haemophilus influenzae type b conjugate vaccines. *WER* 2006; 81: 445–452
66. Dittmann S: Haemophilus influenzae type b (Hib) vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 1569–1572
67. American Academy of Pediatrics: Haemophilus influenzae infections. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006: pp 310–318

### Hepatitis-A-Impfstoff

68. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Hepatitis A, S. 57–59
69. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following hepatitis A vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 11–33
70. Hepatitis A vaccines. WHO position paper. WER 2000; 75: 38–44
71. Beth PB, Feinstone SM: Hepatitis A vaccine. In: Plotkin SA, Orenstein WA (eds.). Vaccines. 4th ed. Saunders, Philadelphia 2004, pp 269–298
72. Dittmann S: Hepatitis vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 1600–1609
73. American Academy of Pediatrics: Hepatitis A. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 326–335

### Hepatitis-B-Impfstoff

74. Stratton KR, Howe CJ, Johnston RB Jr (eds.): Adverse events associated with childhood vaccines. National Academy of Sciences, Washington DC 1994, section hepatitis B vaccines, pp 211–235
75. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. MMWR 1996; 45: No RR-12, section hepatitis B vaccine side effects and adverse reactions, p 7
76. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Hepatitis B, S. 60–66
77. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section adverse events associated with the hepatitis B vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 34–39
78. Chen RT, Mootrey G, DeStefano F: Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: section Hepatitis B Vaccines, pp 282–283
79. Hartmann K, Keller-Stanislawski B: Rekombinante Hepatitis-B-Impfstoffe und Verdachtsfälle unerwünschter Reaktionen. *Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz* 2002; 45: 355–363
80. Mast E, Mahoney FJ, Kane M, Margolis HS: Hepatitis B vaccine. In: Plotkin SA, Orenstein WA (eds.). Vaccines. 4th ed. Saunders, Philadelphia 2004, pp 299–338
81. Hepatitis B vaccines. WHO position paper. WER 2004; 79: 255–263

82. Csepregi A, Treiber G, Röcken C, Malfertheiner P: Acute exacerbation of autoimmune hepatitis induced by Twinrix. *World J Gastroenterol* 2005; 11: 4114–4116
83. American Academy of Pediatrics: Hepatitis B. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 335–355
84. Dittmann S: Hepatitis vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 1600–1609
85. American Academy of Pediatrics: Hepatitis B. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 335–355

### Hepatitis-B-Impfstoff und multiple Sklerose

86. Anonymous. WER 1997; 72: 149–152
87. Medical Advisory Board of the National Multiple Sclerosis Society. Statement from 14 August 1998. National Multiple Sclerosis Society: News Desk Research Bulletin, 3 September 1998
88. Zipp F: No increase in demyelinating disease after hepatitis B vaccination. *Nature Medicine* 1999; 5: 964–965
89. Fourrier A, Touze E, Alperovitch A, Begaud B: Association between hepatitis B vaccine and multiple sclerosis: a case-control study. *Pharmacoepidemiol Drug Safety* 1999; 8: 140–141
90. Sturkenboom MCJM, Abenhaim L, Wolfson C, Roulet E, Heinzelf O, Gout O: Vaccinations. Demyelination, and multiple sclerosis study (VDAMS). *Pharmacoepidemiol Drug Safety* 1999; 8: 170–171
91. Sadovnik AD, Scheifele DW: School-based hepatitis B vaccination programme and adolescent multiple sclerosis. *Lancet* 2000; 355: 549–550
92. Chen RT, Mootrey G, DeStefano F: Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: 282–283
93. Verdier-Taillefer, Lyon-Caen O, Alperovitch A: Premier épisode de Démyélinisation du système nerveux central et vaccination contre l'hépatite B. *Rev Neurol (Paris)* 2000; 156: 242–246
94. Monteyne P, André FE: Is there a causal link between hepatitis B vaccination and multiple sclerosis? *Vaccine* 2000; 18: 1994–2001
95. Gellin BG, Schaffner W: The risk of vaccination – the importance of „negative“ studies. *N Engl J Med* 2001; 344: 372–373
96. Asherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM: Hepatitis B vaccination and the risk of multiple sclerosis. *N Engl J Med* 2001; 344: 327–332

97. DeStefano F, Verstraeten T, Jacksin LA, et al.: Vaccinations and risk of central nervous system demyelinating diseases in adults. *Arch Neurol* 2003; 60:504–509
98. Global Advisory Committee on Vaccine Safety: Hepatitis B vaccination and multiple sclerosis (MS). [http://www.who.int/vaccine\\_safety/topics/hepatitisb/multiple\\_sclerosis/en/index.html](http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/en/index.html)
99. Confavreux C, Suissa S, Saddier P, Bourdes V, Vucusic S: Vaccinations and the risk of relapse in multiple sclerosis. *Vaccines in multiple sclerosis study group. N Engl J Med* 2001; 319–326
100. Hernán MA, Jick SS, Olek MJ, Jick H: Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis. *Neurology* 2004; 63: 838–842
101. Hostetler L: Vaccinations and multiple sclerosis. *N Engl J Med* 2001; 344: 1795
102. Institute of Medicine. Immunization Safety review: – Hepatitis B vaccine and demyelinating neurological disorders. National Academy Press, Washington DC 2002. <http://www.nap.edu/catalog/10393.html> (Zugang: 26 Jan 2007)
103. Dittmann S: Hepatitis vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 1600–1609
104. American Academy of Pediatrics: Risks and adverse events. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 39–41
105. American Academy of Pediatrics: Hepatitis B. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 335–355
106. Multiple Sklerose und Impfung – Hepatitis B-Impfung. <http://www.pei.de> (Zugang 19.2.2007)
109. Gardasil®. Summary of product characteristics (SPC). Merck & CO, INC., Whitehouse Station, NJ 08889, USA, June 2006. <http://www.fda.gov/cber/label/hpv-mero60806LB.pdf> (Zugang 8 Januar 2007)
110. Jenkins D: Prevention of cervical cancer using Cervarix vaccination against HPV 16/18. Symposium „Impfen in Deutschland: Aktuelle Entwicklungen“, Schloss Waldthausen, 26–28 Januar 2006
111. Barr E: Gardasil – quadrivalent HPV (types 6,11,16,18) LI VLP vaccine: duration of efficacy and immunogenicity; safety. Symposium „Impfen in Deutschland: Aktuelle Entwicklungen“, Schloss Waldthausen, 26–28 Januar 2006
112. Quadrivalent human papilloma virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2007; 56, Early Release March 12, 2007
113. HPV and HPV vaccine – Information for Health Care Providers. <http://www.cdc.gov/std/HPV/STDfact-HPV-vaccine-hcp.htm> (Zugang 19.1.2007)
114. CDC: HPV-Vaccine – Questions & Answers. <http://www.cdc.gov/vaccines/vpd-vac/hpv/vac-faqs.htm> (Zugang 19.1.2007)

#### Influenza-Impfstoff

#### Hepatitis-A/Hepatitis-B-Impfstoff

Siehe Literaturangaben bei Hepatitis-A- und Hepatitis-B-Impfstoffen

#### Humaner Papillomvirus-Impfstoff

107. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, for the GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent LI virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *Lancet* 2004; 364: 1757–1765
108. Koutsky LA, Harper DM: Current findings from prophylactic HPV vaccine studies. In: HPV vaccine and screening in prevention of cervical cancer (ed. Bosch FX). *Vaccine* 2006; 24 Suppl 3 pp 114–121
115. Quast U, Thilo W, Fescharek R: *Impfreaktionen – Bewertung und Differentialdiagnose*. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Influenza, S. 67–72
116. Supplementary information on vaccine safety – Background rates of adverse events following immunization, section Adverse events following influenza vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 40–44
117. Institute of Medicine: Immunization Safety Review: Influenza vaccine and neurological complications. National Academy Press, Washington DC 2004. <http://www.nap.edu/catalog/10822.html> (Zugang: 26 Jan 2007)
118. Fukuda K, Coc NJ, Bridges CB, Levandowski RA: Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 339–370
119. Dittmann S: Influenza vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 1753–1758
120. American Academy of Pediatrics: Influenza. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 401–411
121. Influenza vaccines. WHO position paper. *WER* 2005; 80: 279–287

## Masern-Impfstoff

122. Stratton KR, Howe CJ, Johnston RB Jr (eds.): Adverse events associated with childhood vaccines. National Academy of Sciences, Washington DC 1994, section measles and mumps vaccines, pp 118–186
123. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. *MMWR* 1996; 45: No RR-12, section measles vaccine side effects and adverse reactions, p 10
124. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Masern, S. 77–82
125. UK National Childhood encephalopathy study (Committee on Safety of Medicines and the Joint Committee on Vaccination and Immunisation. London, Her Majesty's Stationery office, 1981, pp 79–169
126. Miller D, Wadsworth J, Diamond J, Ross E: Measles vaccination and neurological events. *Lancet* 1997; 349: 730–731
127. Duclos P, Ward BJ: Measles vaccines. A review of adverse events. *Drug Safety* 1998; 19: 435–454
128. Bitnun A, Shannon P, Durward A et al.: Measles Inclusion-body encephalitis caused by the vaccine strain of measles virus. *Clin Infect Dis* 1999; 29: 855–861
129. Hartmann K, Keller-Stanislawski B: Verdachtsfälle unerwünschter Arzneimittelnebenwirkungen nach Anwendung von Impfstoffen mit attenuierter Masernkomponente. *Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz* 2001; 44: 981–986
130. Measles vaccines. WHO position paper. *WER* 2004; 79: 130–142
131. Strebel PM, Parania MJ, Halsey NA: Measles vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 389–440
132. Dittmann S: Measles, mumps, rubella vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 2207–2223
133. American Academy of Pediatrics: Measles. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 441–452
134. Measles vaccine and SSPE. Global Advisory Committee on Vaccine Safety, 1–2 December 2005. *WER* 2006, 81: 15–18
135. Ray P, Hayward J, Michelson D et al.: The Vaccine Safety Datalink Group. *Ped Infect Dis J* 2006; 25: 768–773
137. Haga Y, Funagoshi O, Kuroe K et al.: Absence of measles viral genomic sequences in intestinal tissues from Crohn's disease by nested polymerase chain reaction. *Gut* 1996; 38: 211–215
138. Wing L: Autism spectrum disorders: no evidence for or against an increase in prevalence. *Br Med J* 1996; 312: 327–328
139. Fisher NC, Yee L, Nightingale P et al.: Measles virus serology in Crohn's disease. *Gut* 1997; 41: 66–69
140. Gilat T, Hacoheh D, Lilos P et al.: Childhood factors in ulcerative colitis and Crohn's disease. *Scand J Gastroenterol* 1997; 22: 1009–24
141. Nielsen LLW, Nielsen NM, Melbye M et al.: Exposure to measles in utero and Crohn's disease: a Danish register study. *Br Med J* 1998; 316: 196–197
142. Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M: No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. *Lancet* 1998; 351: 1327–1328
143. Yamashita Y, Walker-Smith A, Shimizu T, Oguchi S, Ohtsuka Y: Measles vaccination and inflammatory bowel disease in Japanese children. Letter to the editor. *J Pediatr Gastroenterol Nutr* 1998; 26: 238
144. Wakefield AJ, Murch SH, Linnell AAJ, Casson DM, Malik M, Bewrelowitz M: Ileal-lymphoid-nodular hypoplasia, non-specific colitis and pervasive developmental disorder in children. *Lancet* 1998; 351: 637–641
145. Taylor-B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Jun Li, Waight PA: Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. *Lancet* 1999; 353: 2026–2029
146. Patja A, Davidkin I, Kurki T, Kallio MJT, Valle M, Peltola H: Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. *Pediatr Infect Dis J* 2000; 19: 1127–1134
147. Halsey NA, Hyman SL, and the conference writing panel. Electronic article: Measles-mumps-rubella vaccine and autistic spectrum disorder: Report from the new challenges in childhood immunizations conference convened in Oak Brook, Illinois, June 12–13, 2000. *Pediatrics* 2001; 107: e84
148. Institute of Medicine: Immunization Safety Review: Measles-mumps-rubella vaccine and autism. National Academy Press, Washington DC 2001. <http://www.nap.edu/catalog/10101.html> (Zugang: 26 Jan 2007)
149. Uhlmann V, Martin CM, Sheils O, Pilkington L, Silva I, Killalea A, Murch SB, Wakefield AJ, O'Leary JJ: Potential viral pathogenic mechanism for new variant inflammatory bowel disease. *Molecular Pathology* 2002; 55: 84–90
150. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J: Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. *Brit Med J* 2002; 324: 393–396

## Masern-Impfstoff, MMR-Impfstoff und Autismus sowie Morbus Crohn

136. Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ: Is measles vaccination a risk factor for inflammatory bowel disease? *Lancet* 1995; 345: 1071–1074

151. Measles vaccines. WHO position paper. WER 2004; 79: 130–142
152. Dittmann S: Measles, mumps, rubella vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 2207–2223
153. American Academy of Pediatrics: Risks and adverse events. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 39–41
154. CDC: References used to research the answers to questions about vaccines and autism. <http://www.cdc.gov/nip/vacsafe/concerns/autism/autism-ref.htm> (Zugang: 26 Jan 2007)
155. CDC: Frequently asked questions on measles vaccine and inflammatory bowel disease (including list of references). <http://www.cdc.gov/nip/vacsafe/concerns/autism/ibd.htm> (Zugang: 26 Jan 2007)
156. Doja A, Roberts W: Immunizations and Autism: A Review of the Literature. Can J Neurol Sci 2006; 33: 341–346
157. Stratton KR, Howe CJ, Johnston RB Jr (eds.): Adverse events associated with childhood vaccines. National Academy of Sciences, Washington DC 1994, section measles and mumps vaccines, pp 118–186
158. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section measles, mumps and rubella vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 55–68
159. Chen RT, Mootrey G, DeStefano F: Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: section MMR vaccination, pp 283–284
160. Plesner AM, Hansen FJ, Taudorf K, Nielsen LH, Larsen CB: Gait disturbance interpreted as cerebellar ataxia after MMR vaccination at 15 months of age: a follow-up study. *Acta Paediatr* 2000; 89: 58–63
161. Hartmann K, Keller-Stanislawski B: Verdachtsfälle unerwünschter Arzneimittelnebenwirkungen nach Anwendung von Impfstoffen mit attenuierter Masernkomponente. *Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz* 2001; 44: 981–986
162. Miller E, Waight P, Farrington P, Andrews N, Stowe J, Taylor B: Idiopathic thrombocytopenic purpura and MMR vaccine. *Arch Dis Child* 2001; 84: 221–229
163. Institute of Medicine: Immunization Safety Review: Measles-mumps-rubella vaccine and autism. National Academy Press, Washington DC 2001. <http://www.nap.edu/catalog/10101.html> (Zugang: 26 Jan 2007)
164. Global Advisory Committee on Vaccine Safety: MMR and autism. WER 2003; 78: 18–19
165. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfart J, Thorsen P, Olsen J, Melbye M: A population-based study of MMR and autism. *NEJM* 2002; 347: 1477–1482
166. Dittmann S: Measles-mumps-rubella (MMR) vaccine, including MMR and autism and Crohn's disease. In: *Side Effects of Drugs Annual 25* (ed. Aronson JK). Elsevier, Amsterdam 2002, pp 387–389
167. Measles vaccines. WHO position paper. WER 2004; 79: 130–142
168. Institute of Medicine: Immunization Safety Review: Vaccines and autism. National Academies Press, Washington, D.C., 2004. <http://www.nap.edu/catalog/10997.html> (Zugang: 26 Jan 2007)
169. American Academy of Pediatrics: Measles. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 441–452
170. Dittmann S: Measles, mumps, rubella vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 2207–2223

### MMR-Impfstoff

171. American Academy of Pediatrics: Measles. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 441–452
- Ferner siehe MMR- und Varizellen-Impfstoff
172. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Meningokokken-Erkrankung, S. 83–86
173. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following meningococcal polysaccharide vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 51–54
174. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. WHO position paper. WER 2002; 77: 331–339
175. Dittmann S: Meningokokken-Erkrankungen. Thieme, Stuttgart 2003, S. 52
176. Granoff DM, Feavers IM, Borrow R: Meningococcal vaccines. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 959–988
177. Dittmann S: Meningococcal vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, 2250–2253

### MMR-V-Impfstoff

171. American Academy of Pediatrics: Measles. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 441–452
- Ferner siehe MMR- und Varizellen-Impfstoff
172. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Meningokokken-Erkrankung, S. 83–86
173. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following meningococcal polysaccharide vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 51–54
174. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. WHO position paper. WER 2002; 77: 331–339
175. Dittmann S: Meningokokken-Erkrankungen. Thieme, Stuttgart 2003, S. 52
176. Granoff DM, Feavers IM, Borrow R: Meningococcal vaccines. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 959–988
177. Dittmann S: Meningococcal vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, 2250–2253

### Meningokokken-(Konjugat)-Impfstoff

178. Richmond P, Goldblatt D, Fusco PC, Fusco DJS, Heron I: Safety and immunogenicity of a new *Neisseria meningitidis* serogroup C tetanus conjugate vaccine in healthy adults. *Vaccine* 1999; 18: 641–646
179. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flammank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER: Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. *J Am Med Assoc* 2000; 283: 2795–2801
180. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. WHO position paper. *WER* 2002; 77: 331–339
181. Dittmann S: Meningokokken-Erkrankungen. Thieme, Stuttgart 2003, S. 60–66
182. Abeyagunawardena AS, Goldblatt D, Andrews N, Trompeter RS: Risk of relapse after meningococcal conjugate vaccine in nephritic syndrome. *Research letter. Lancet* 2003; 362: 449–450
183. Granoff DM, Feavers IM, Borrow R: Meningococcal vaccines. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 959–988
184. American Academy of Pediatrics: Meningococcal infections. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 452–460
185. Dittmann S: Meningococcal vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, 2250–2253

### Mumps-Impfstoff

186. Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV): Mumpfschutzimpfung und Diabetes mellitus (Typ I). *Bundesgesundheitsblatt* 1989; 32: 237
187. Stratton KR, Howe CJ, Johnston RB Jr (eds.): Adverse events associated with childhood vaccines. National Academy of Sciences, Washington DC 1994, section measles and mumps vaccines, pp 118–186
188. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. *MMWR* 1996; 45: No RR-12, section mumps vaccine adverse effects of vaccine use, p 19
189. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Mumps, S. 87–93
190. Plotkin SA: Mumps vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 441–470
191. Dittmann S: Measles, mumps, rubella vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions

(ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 2207–2223

192. American Academy of Pediatrics: Mumps infections. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 464–468
193. American Academy of Pediatrics: Measles. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 441–452
194. Mumps vaccine-associated meningitis. WHO Global Advisory Committee on Vaccine Safety, 29–30 November 2006. *WER* 2007, 82: 18–24

### Pneumokokken (Polysaccharid)-Impfstoff

195. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Pneumokokkenerkrankung, S. 100–103
196. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following pneumococcal vaccine. WHO, Geneva 2000. WHO/V&B/00.36. pp 69–71
197. Overturf GD, Peter G, Pickering LK, MacDonald NE, Chilton L, Jacobs RF, Delage G, Dowell SF, Orenstein WA, Patriarca PA, Myers MG, Ledbetter EO, Kim J: Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. *Pediatrics* 2000; 106: 367–376
198. Pneumococcal vaccines. WHO position paper. *WER* 2003; 78: 110–119
199. Fedson DS, Musher DM: Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 529–588
200. Dittmann S: Pneumococcal vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 2873–2877
201. American Academy of Pediatrics: Pneumococcal infections. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 525–537

### Pneumokokken (Konjugat)-Impfstoff

202. Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, Hackell J, Paradiso PR, Siber G, Kohberger R, Madore DV, Malinowski FJ, Kimura A, Le C., Landaw I, Aguilar J, Hansen J: Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine



- in infants and toddlers. *Pediatr Infect Dis J* 1999; 18: 757–63
203. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K, Aguilar J, Bartlett M, Bergen R, Burman M, Dorfman S, Easter W, Finkel A, Froehlich H, Glauber J, Herz A, Honeychurch D, Kleinrock R, and the Northern California Kaiser Permanente Vaccine Study Center group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. *Pediatr Infect Dis J* 2000; 19: 187–195
204. Overturf GD, Peter G, Pickering LK, MacDonald NE, Chilton L, Jacobs RF, Delage G, Dowell SF, Orenstein WA, Patriarca PA, Myers MG, Ledbetter EO, Kim J: Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. *Pediatrics* 2000; 106: 367–376
205. Kalies H, Hermann M, Schmitt HJ, von Kries R: Prävention invasiver Pneumokokkeninfektionen im Kindesalter. *Kinderärztl Prax* 2001; 72: 31–36
206. Volz S, Habermehl P, Zell A, Knuf M: Pneumokokken und Pneumokokkenimpfstoffe: Bedeutung für die Pädiatrie. *Monatsschr Kinderheilkunde* 2001; 149: 394–409
207. Schmöle-Thoma B: 7-valenter Konjugatimpfstoff Prevenar: Immunogenität, Reaktogenität und Wirksamkeit. *Kinderärztl Prax* 2001; 72, Sonderheft Pneumokokkenimpfung, S. 16–21
208. Pneumococcal vaccines. WHO position paper. *WER* 2003; 78: 110–119
209. Eskola J, Black SB, Shinefield H: Pneumococcal conjugate vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 589–624
210. American Academy of Pediatrics: Pneumococcal infections. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 525–537
211. Dittmann S: Pneumococcal vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 2873–2877
212. Safety of pneumococcal conjugate vaccine. WHO Global Advisory Committee on Vaccine Safety, 29–30 November 2006. *WER* 2007, 82: 18–24
- cautions. *MMWR* 1996; 45: No RR-12, section poliomyelitis vaccine adverse reaction, p 8
215. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. Hippokrates Verlag, Stuttgart 1993, Kapitel Poliomyelitis, S. 105–112
216. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Poliomyelitis, S. 104–111
217. Chen RT, Mootrey G, DeStefano F: Safety of routine childhood vaccinations: – An epidemiological review. *Pediatr Drugs* 2000; 2: section inactivated and oral poliovirus vaccines, pp 280–281
218. Introduction of inactivated poliovirus vaccines into oral poliovirus vaccine-using countries. WHO position paper. *WER* 2003; 78: 241–250
219. Plotkin SA, Vidor E: Inactivated polio vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 625–650
220. American Academy of Pediatrics: Poliovirus infections. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 542–547
221. Dittmann S: Poliomyelitis vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 2881–2887
222. American Academy of Pediatrics: Poliovirus infections. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 542–547

### Röteln-Impfstoff

### Poliomyelitis-Impfstoff (inaktiviert – IPV)

213. Stratton KR, Howe CJ, Johnston RB Jr (eds.): Adverse events associated with childhood vaccines. National Academy of Sciences, Washington DC 1994, section polio vaccines, pp 187–210
214. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and pre-
223. Howson CP, Howe CJ, Fineberg HV (eds.): Adverse effects of pertussis and rubella vaccines. A report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. National Academy Press, Washington DC 1991
224. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Röteln, S. 112–118
225. Rubella vaccines. WHO position paper. *WER* 2000; 75: 161–169
226. Plotkin SA, Reef S: Rubella vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, 704–744
227. Dittmann S: Measles, mumps, rubella vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). Elsevier, Amsterdam 2006, pp 2207–2223
228. American Academy of Pediatrics: Rubella. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 574–579

### Rotavirus-Impfstoff

229. Recommendation of the American Committee on Immunization Practices (ACIP): Prevention of rotavirus gastroenteritis among infants and children. *MMWR* 2006; 55 No RR-12
230. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR et al. for the Human Rotavirus Vaccine Study Group: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. *N Engl J Med* 2006; 354: (1) 11–22
231. Vesikari T, Matson DO, Dennehy P et al. for the Rotavirus Efficacy and Safety Trial (REST) Study Team: Safety and Efficacy of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine. *N Engl J Med* 2006; 354: (1) 23–33
232. Mitteilung der Ständigen Impfkommision (STIKO) am Robert Koch-Institut: Fragen und Antworten zur Möglichkeit einer Impfung gegen Rotavirus-Erkrankungen. *Epid Bull* 2007; 2: 9–11

### Tetanus-Impfstoff

233. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Tetanus, S. 119–124
234. Dittmann S: Tetanus vaccine. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 3325–3327
235. American Academy of Pediatrics: Tetanus. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 648–653
236. Tetanus toxoid vaccines. WHO position paper. *WER* 2006; 81: 198–208

### Tetanus-Diphtherie-Pertussis (azellulär): Tdap-Impfstoff

237. Van der Wielen M, Van Damme P, Joossens E, François G, Meurice F, Ramalho A: A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. *Vaccine* 2000; 18: 2075–2082
238. Kretsinger K, Broder KR, Cortese MM, Joyce MP, Ortega-Sanchez I, Lee GM, Tiwari T, Cohn AC, Slade BA, Iskander J K, Mijalski CM, Brown KH, Murphy TV: Preventing Tetanus, Diphtheria, and Pertussis Among Adults: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, Supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Healthcare Personnel. *MMWR* 2006; 55 (RR-17)
239. Frampton JE, Keating GM: Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix (Trade Mark)): A review of its use as a

single-dose booster Immunization. *BioDrugs*; 2006; 20: 371–389

### Tollwut-Impfstoff

240. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Tollwut, S. 125–131
241. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following rabies vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 79–83
242. Rabies vaccines. WHO position paper. *WER* 2002; 77: 109–119
243. Plotkin SA, Rupprecht CE, Koprowski H: Rabies vaccine. In: Plotkin SA, Orenstein WA (eds.). Vaccines. 4th ed. Saunders, Philadelphia 2004, 1011–1038
244. Dittmann S: Rabies vaccine. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 3012–3013
245. American Academy of Pediatrics: Rabies. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 552–559

### Typhus-Oral-Impfstoff und Typhus-Polysaccharid-Impfstoff

246. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Typhus abdominalis, S 140–145
247. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following typhoid vaccine. WHO, Geneva 2000. WHO/V&B/00.36, pp 89–92
248. Typhoid vaccines. WHO position paper. *WER* 2000; 75: 257–264
249. Levine MM: Typhoid fever vaccines. In: Plotkin SA, Orenstein WA (eds.). Vaccines. 4th ed. Saunders, Philadelphia 2004, pp 1057–1094
250. Dittmann S: Typhoid fever vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). 15th ed. Elsevier, Amsterdam 2006, pp 3538–3540

### Varizellen-Impfstoff

251. Quast U, Thilo W, Fescharek R: Impfreaktionen – Bewertung und Differentialdiagnose. 2. Aufl. Hippokrates Verlag, Stuttgart 1997, Kapitel Varizellen, Zoster. S. 146–150
252. Varicella vaccines. WHO position paper. *WER* 1998; 73: 241–248
253. Wise RT, Salive ME, Braun M, Mootrey GT, Seward JF, Rider LG, Krause PR: Postlicensure safety for varicella vaccine. *J Amer Med Assoc* 2000; 284: 1271–1279

254. Supplementary information on vaccine safety – Background rates of adverse events following immunization. Section Adverse events following varicella vaccine. WHO, Geneva 2000. WHO/V&B/00.3, pp 93–96
255. Sharrar RG, La Russa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson W, Gershon A: The postmarketing safety profile of varicella vaccine. *Vaccine* 2001; 19: 916–923
256. Gershon AA, Takahashi M, Seward J: Varicella vaccine. In: Plotkin SA, Orenstein WA (eds.). *Vaccines*. 4th ed. Saunders, Philadelphia 2004, pp 783–824
257. Dittmann S: Varicella vaccine. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). Elsevier, Amsterdam 2006, pp 3606–3609
258. American Academy of Pediatrics: Varicella-Zoster infections. In: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006, pp 711–725
270. Plotkin SA, Orenstein WA (eds.): *Vaccines*. 4th ed. Saunders, Philadelphia 2004
271. American Academy of Pediatrics: Pickering LK, Baker CJ, Long SS, Mc Millan JA (eds.). *Red Book: 2006 Report of the Committee on Infectious Diseases*. 27th ed. Elk Grove Village, IL; American Academy of Pediatrics 2006
272. Dittmann S: Monographs on cholera (pp 736–737), diphtheria (pp 1137–1140), haemophilus influenzae type b (pp 1569–1572), hepatitis (pp 1600–1609), human papillomavirus (p 1699), influenza (pp 1753–1758), measles-mumps-rubella (pp 2207–2223), meningococcal (pp 2250–2253), pertussis (pp 2783–2790), pneumococcal (pp 2873–2877), poliomyelitis (pp 2881–2887), rabies (pp 3012–3013), rotavirus (pp 3082–3083), tetanus toxoid (pp 3325–3327), tickborne meningoencephalitis (pp 3423–3424), typhoid fever (pp 3538–3540, varicella (pp 3606–3609), yellow fever (pp 3703–3704) vaccines. In: Meyler's Side Effect of Drugs: the international encyclopedia of adverse drug reactions and interactions (ed. Aronson JK). Elsevier, Amsterdam 2006

## Übersichtsliteratur

259. Howson CP, Howe CJ, Fineberg HV (eds.): Adverse effects of pertussis and rubella vaccines. A report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. National Academy Press, Washington DC 1991
260. Stratton KR, Howe CJ, Johnston RB Jr (eds.): Adverse events associated with childhood vaccines. National Academy of Sciences, Washington DC 1994
261. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Update: Vaccine side effects, adverse reactions, contraindications, and precautions. *MMWR* 1996; 45: No RR-12
262. Quast U, Thilo W, Fescharek R: *Impfreaktionen – Bewertung und Differentialdiagnose*. 2. Aufl. Hippokrates Verlag, Stuttgart 1997
263. Supplementary information on vaccine safety – Background rates of adverse events following immunization. WHO, Geneva 2000. WHO/V&B/00.36
264. Chen RT, Mootrey G, DeStefano F: Safety of routine childhood vaccinations: An epidemiological review. *Pediatr Drugs* 2000; 2: 273–290
265. Dittmann S: Das Risiko des Impfens und das weit größere Risiko nicht geimpft zu sein. *Bundesgesundheitsblatt* 2002; 45: 316–320
266. Jilg W, Dittmann S: *Impfen (CD-ROM, 3. Aufl.)*. Thieme, Stuttgart 2002
267. *Handbuch Infektionen bei Kindern und Jugendlichen*. Herausgegeben von der Deutschen Gesellschaft für pädiatrische Infektiologie. 4. Aufl. Futuramed, München 2003
268. *Schutzimpfungen*, 3. Aufl. 2003 (Hrsg. Schmitt HJ, Hülße C, Raue W). Infomed, Berlin 2003
269. Dittmann S: Impfung: wirksamer Schutz oder Risiko? Wissensstand und Wissenslücken zu Impfnebenwirkungen. *Med Welt* 2004; 55: 175–180
273. Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten (DVV): *Mumpsschutzimpfung und Diabetes mellitus (Typ I)*. *Bundesgesundheitsbl* 1989; 32: 237
274. Stratton KR, Howe CJ, Johnston RB Jr (eds.): Adverse events associated with childhood vaccines. National Academy of Sciences, Washington DC 1994, pp 154–159, 306
275. Jefferson T: Vaccination and its adverse effects: Real or perceived *Br Med J* 1998; 317: 159–160
276. Childhood immunizations and type 1 diabetes. Summary of an Institute for Vaccine Safety workshop. *Pediatr Infect Dis J* 1999; 18: 217–222
60. Von Kries R, Schmitt HJ: Diabetes mellitus nach Hib-Impfung? *Kinderärztl Prax* 1999; 70: 589–590
63. Trampisch HJ, Lange S: Diabetes mellitus nach Hib-Impfung? Die Diskussion geht weiter. *Kinderärztl Prax* 2000; 71: 6–10
277. DeStefano F, Mullooly J, Okoro CA, Chen RT, Marcy M, Ward JI, Vadheim C, Black SB, Shinefield H, Davis RL, Bohlke K, and the Vaccine Safety Datalink Team: Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. *Pediatrics* 2002; 108: e112
278. Institute of Medicine: *Immunization Safety Review: Multiple immunizations and immune dysfunction (parts multiple immunization and diabetes)*. National Academy Press, Washington DC 2002, pp 1–22, 45–47. <http://www.nap.edu/catalog/10306.html> (Zugang: 26 Jan 2007)
279. Keller-Stanislawski B, Hartmann K: Existiert ein Zusammenhang zwischen Impfungen und Typ 1-Diabetes mellitus und Impfungen bei Kindern und Jugendlichen? *Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz* 2001; 44: 613–618

## Kinderimpfstoffe und Diabetes

280. Hviid A, Stellfield M, Wohlfart J, Melbye M: Childhood vaccination and type 1 diabetes. *N Engl J Med* 2004; 350: 1398–1404

### Fremdstoffe in Impfstoffen

281. Global Advisory Committee on Vaccine Safety, 3–4 December 2003: Aluminium-containing vaccines and macrophagic myofasciitis. *WER* 2004; 79: 20
282. Global Advisory Committee on Vaccine Safety, 6–7 June 2006: Safety of squalene. *WER* 2006; 81: 274–275
283. Global Advisory Committee on Vaccine Safety, 29–30 November 2006: Safety of vaccine formulations. *WER* 2007; 2: 20
284. Global Advisory Committee on Vaccine Safety, 20–21 June 2002: Safety of thiomersal-containing vaccines. *WER* 2002; 7: 390
285. Global Advisory Committee on Vaccine Safety, 2–3 December 2004: Thiomersal: Neurobehavioural studies in animal models. *WER* 2005; 80: 3–4
286. Global Advisory Committee on Vaccine Safety, 9–10 June 2005: Thiomersal. *WER* 2005; 80: 244–245
287. Immunization Safety Review: Thimerosal-containing vaccines and neurodevelopmental disorders. National Academy of Sciences, Washington DC 2001
288. Immunization Safety Review: Vaccines and autism. National Academy of Sciences, Washington DC 2004
289. Thiomersal und Impfungen. <http://www.pei.de> (Zugang 18.3.2007)
290. Weisser K, Bauer K, Volkers P, Keller-Stanislawski B: Thiomersal und Impfungen. *Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz* 2004; 47: 1165–1174
291. Lindblad E: Aluminium adjuvants – in retrospect and prospect. *Vaccine* 2004; 22: 3658–3668
292. Gherardi RK, Coquet M, Chérin P et al.: Macrophagic myofasciitis: an emerging entity. *Lancet* 1988; 352: 347–352
293. Brenner A: Macrophagic myofasciitis: a summary of Dr Gherardi's presentation. *Vaccine* 2002, 20: 5–6
294. Henning HV: Die Toxizität des Aluminiums. *Klin Wochenschr* 1989; 67: 1221–1228
295. Flarend RE et al.: In vivo absorption of aluminium-containing vaccine adjuvants using Al. *Vaccine* 1997; 15: 1314–1318
296. Adsorbenzien. In: Quast U, Thilo W, Fescharek R: *Impfreaktionen. Bewertung und Differenzialdiagnose*. 2. Aufl. Hippokrates Verlag Verlag, Stuttgart 1997, S. 187
297. Global Advisory Committee on Vaccine Safety (GACVS): Aluminium-containing vaccines and macrophagic myofasciitis. *WER* 2002; 77: 392–393
298. Netterlid E, Bruze M, Hindsen M, Isaksson M, Olin P: Persistent itching nodules after the forth dose of diphtheria-tetanus toxoid vaccines without evidence of delayed hypersensitivity to aluminium. *Vaccine* 2004; 22: 3698–3706
299. European Pharmacopoeia. Supplement 5.8. Council of Europe, 2007. Vaccines for Human Use, monograph 0153

## Impressum

### Herausgeber

Robert Koch-Institut  
Nordufer 20, 13353 Berlin

Tel.: 030 18. 754-0  
Fax: 030 18. 754-26 28  
E-Mail: [EpiBull@rki.de](mailto:EpiBull@rki.de)

### Redaktion

- ▶ Dr. med. Jamela Seedat (v. i. S. d. P.)  
Tel.: 030 18. 754-23 24  
E-Mail: [SeedatJ@rki.de](mailto:SeedatJ@rki.de)
- ▶ Dr. med. Ulrich Marcus (Vertretung)  
E-Mail: [MarcusU@rki.de](mailto:MarcusU@rki.de)
- ▶ Mitarbeit: Dr. sc. med. Wolfgang Kiehl

### Redaktionsassistentz

Sylvia Fehrmann  
Tel.: 030 18. 754-24 55  
E-Mail: [FehrmannS@rki.de](mailto:FehrmannS@rki.de)  
Fax.: 030 18. 754-24 59

### Vertrieb und Abonnentenservice

Plusprint Versand Service Thomas Schönhoff  
Bücher Weg 18, 16321 Lindenberg  
Abt.-Tel.: 030. 94 87 81-3

### Das Epidemiologische Bulletin

gewährleistet im Rahmen des infektions-epidemiologischen Netzwerks einen raschen Informationsaustausch zwischen den verschiedenen Akteuren – den Ärzten in Praxen, Kliniken, Laboratorien, Beratungsstellen und Einrichtungen des öffentlichen Gesundheitsdienstes sowie den medizinischen Fachgesellschaften, Nationalen Referenzzentren und den Stätten der Forschung und Lehre – und dient damit der Optimierung der Prävention.

Herausgeber und Redaktion erbitten eine aktive Unterstützung durch die Übermittlung allgemein interessierender Mitteilungen, Analysen und Fallberichte. Das Einverständnis mit einer redaktionellen Überarbeitung wird dabei vorausgesetzt.

Das *Epidemiologische Bulletin* erscheint in der Regel wöchentlich (50 Ausgaben pro Jahr). Es kann im Jahresabonnement für einen Unkostenbeitrag von € 49,- per Beginn des Kalenderjahres bezogen werden; bei Bestellung nach Jahresbeginn errechnet sich der Beitrag mit € 4,- je Bezugsmonat. Ohne Kündigung bis Ende November verlängert sich das Abonnement um ein Jahr.

Die **aktuelle** Ausgabe des *Epidemiologischen Bulletins* kann über die **Fax-Abbruffunktion** unter 030 18. 754-22 65 abgerufen werden. Die Ausgaben ab 1997 stehen im **Internet** zur Verfügung: [www.rki.de](http://www.rki.de) > Infektionsschutz > Epidemiologisches Bulletin.

### Druck

MB Medienhaus Berlin GmbH

### Nachdruck

mit Quellenangabe gestattet, jedoch nicht zu werblichen Zwecken. Belegexemplar erbeten. Die Weitergabe in elektronischer Form bedarf der Zustimmung der Redaktion.

ISSN 1430-0265 (Druck)  
ISSN 1430-1172 (Fax)  
PVKZ A-14273